Dr. Vishal Navani leads Calgary’s thoracic oncology clinical trials program and early-phase drug development unit, with a focus on translating innovative science into impactful cancer care. He has served as Principal Investigator on dozens of clinical trials across phases I–III, and sits on several national and international trial steering committees.
As Director of Glans Look Research, he oversees North America’s largest real-world evidence (RWE) database in thoracic malignancies, advancing precision oncology and population-level insights. His research has attracted over $1.5 million in competitive grant funding, including a recent award from the Terry Fox Marathon of Hope Cancer Centres Network for his work in data science and patient reported outcomes.
Dr. Navani is also a recognized thought leader in clinical evidence generation, contributing as a clinical expert to the Canadian Drug Agency (CDA) in support of national drug reimbursement and policy deliberations. In parallel, he collaborates closely with the life sciences sector, providing strategic guidance on clinical development, trial design, and real-world evidence integration. His academic work has been published in leading journals including Journal of Clinical Oncology, JAMA Oncology, and The Lancet Oncology, reflecting a commitment to high-impact, peer-reviewed research at the interface of clinical innovation and patient care.
He holds a MA (Honours) from Oxford, MBBS from London (Imperial College) & is board certified in Canada, Australia & the UK.